论文部分内容阅读
近来研究表明,阿霉素、正定霉素、柔红霉素、米托蒽醌可引起心肌病变,蒽环类或蒽醌类抗癌药亦如此。Dexrazoxane(ADR-529)是一种乙烯二胺四醋酸哌嗪衍生物,本文研究本品预防上述药物引起的心肌病变。作用机理通常认为,蒽环类的心脏毒性与自由基形成有关,在铁存在的情况下,自由基在心脏中充当氧化剂。Dexrazoxane是一种强大的铁螯合物,从理论上讲,这种药物因可螯合游离铁和与蒽环类形成的复合物的铁,故有预防蒽环类引起心脏毒性的作用。在动物中,这种螯合物对阿霉素的心脏毒性有保护作用,并不干扰药物的抗肿瘤作用。
Recent studies have shown that doxorubicin, doxorubicin, daunorubicin, mitoxantrone can cause myocardial lesions, anthracycline or anthraquinone anti-cancer drugs as well. Dexrazoxane (ADR-529) is a ethylenediaminetetraacetic acid piperazine derivative, this study to prevent the drug-induced cardiomyopathy. Mechanism of action It is generally accepted that anthracycline cardiotoxicity is associated with the formation of free radicals and that in the presence of iron, free radicals act as oxidants in the heart. Dexrazoxane is a powerful iron chelate that theoretically has the effect of preventing anthracycline-induced cardiotoxicity by chelating iron with free iron and complexes with anthracyclines. In animals, this chelate has a protective effect on doxorubicin cardiotoxicity and does not interfere with the anti-tumor effect of the drug.